Compare Abeona Therapeutics Inc (ABEO) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Equinix Inc — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Equinix Inc trades at $1,067.9 (market cap $101.87B). The key difference: Equinix Inc is far larger — about 241.9× Abeona Therapeutics Inc's market cap, and Equinix Inc pays a 2% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EQIX | |
|---|---|---|
Market Cap | $421.19M | $101.87B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $1.12K |
52-Week Low | $4.17 | $726.09 |
Enterprise Value | $276.10M | $123.00B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Equinix (EQIX) trades at $1,049.99, up 0.63% today, with a neutral technical signal as it hovers near resistance at $1,050. The stock shows strong analyst support (74.51% buy ratings) and a consensus price target of $1,120, driven by robust revenue growth, expanding net income margins to 15.63% in 2025, and positive news on AI infrastructure demand. However, high valuation ratios like a P/E of 66.44 and significant capital expenditures pose challenges.
The outlook remains positive due to sustained digital infrastructure demand and raised long-term guidance, but risks include elevated debt levels and earnings misses in recent quarters. Investors should weigh growth prospects against premium valuations and cash flow pressures from heavy investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
